Aurora Cannabis Surpasses 2,000 Registered Patients in Four Months
Accelerating Customer Registration Makes Company One of Canada’s Fastest-Growing Licensed Producers
VANCOUVER, BRITISH COLUMBIA–(Marketwired – May 9, 2016) – Aurora Cannabis Inc. (CSE:ACB)(FRANKFURT:21P)(OTCQB:ACBFF) (WKN:A1C4WM) (“Aurora” or the “Company”) announced that the Company has surpassed 2,000 registered patients over its first four months of product sales. With its first sale of product on January 5, 2016, and at the current rate of patient registration, Aurora is one of the fastest-growing Licensed Producers of medical cannabis in Canada.
As previously announced on March 31, 2016, Aurora had registered 1,000 patients less than three months after commencing product sales. This is believed to be the shortest time required to achieve that milestone of any Licensed Producer under Health Canada’s Marihuana for Medical Purposes Regulations (MMPR). Since that time, patient registration and product sales have accelerated further.
This unprecedented level of performance continues to validate our aggressive business plan and allows us to accelerate the next phase of our growth strategy.
Terry Booth, CEO of Aurora.
We are very pleased with our operations as reflected by our growing patient acquisition rate, consistent product quality and low-cost production. In addition, our customer care team and logistics operations are well positioned to handle increasing demand, while patients are reporting that they are extremely satisfied with both the product quality and service received from Aurora.
The Company is currently reviewing a number of options to increase its production capacity to handle both the projected future demand in the medical cannabis market as well as the eventual non-medical consumer market. The Canadian government’s announcement of its intent to introduce legislation in spring 2017 to legalize the recreational use of marijuana creates an additional opportunity that licensed producers and early movers such as Aurora are well positioned to capitalize on.
About Aurora
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Alberta, Canada. Aurora trades on the Canadian Securities Exchange under the symbol “ACB”.
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth, CEO
The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this news release. We seek Safe Harbour.
CONTACT INFORMATION
Aurora Cannabis Inc.
Cam Battley
SVP Communications and Medical Affairs
+1.905.864.5525
cam@auroramj.com
www.auroramj.com
NATIONAL Equicom
Marc Lakmaaker
+1 416 848 1397
mlakmaaker@national.ca
Original press release: http://www.marketwired.com/press-release/aurora-cannabis-surpasses-2000-registered-patients-in-four-months-cnsx-acb-2122557.htm
